WHO ICTRP trial
To evaluate the effect of renogrit in protecting kidneys from side effects of…
CTRI/2025/02/080059 · Clinical Trials Registry India (CTRI) · Not Recruiting
Key facts
| Trial ID | CTRI/2025/02/080059 |
|---|---|
| Public title | To evaluate the effect of renogrit in protecting kidneys from side effects of cisplatin in patients with advanced cancers. |
| Scientific title | A randomized clinical trial to assess the nephroprotective efficacy of renogrit in patients receiving Cisplatin based chemotherapy in advanced or metastatic solid tumors. - NIL |
| Primary sponsor | Patanjali research institute (Divya Pharmacy) |
| Registry | Clinical Trials Registry India (CTRI) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase 3 |
| Countries | India |
| Conditions | Health Condition 1: C39- Malignant neoplasm of other and ill-defined sites in the respiratory system and intrathoracic organs |
| Registration date | Jul 2, 2025 |
| Target size | 220 |
| Secondary IDs | NIL |
| Registry page | ctri.nic.in |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: